Showing results (121-130 of 130) with videos related to
Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
Nature Communications|January 21, 2026
WDR5 remodels NANOG condensates to drive transcriptional programs and sustain stem cell identityDuo Wang, Xianle Shi, Jiaying Xie, et al.Journal of Medicinal Chemistry|February 27, 2019
Development of Highly Potent, Selective, and Cellular Active Triazolo[1,5- a]pyrimidine-Based Inhibitors Targeting the DCN1-UBC12 Protein-Protein InteractionShuai Wang, Lijie Zhao, Xiao-Jing Shi, et al.Journal of Medicinal Chemistry|March 13, 2024
Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor RegressionZhixiang Chen, Mi Wang, Dimin Wu, et al.Journal of Medicinal Chemistry|March 26, 2024
Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate CancerZhixiang Chen, Mi Wang, Dimin Wu, et al.Nature|October 2, 2024
RNA m<sup>5</sup>C oxidation by TET2 regulates chromatin state and leukaemogenesisZhongyu Zou, Xiaoyang Dou, Ying Li, et al.Nature Chemical Biology|February 2, 2023
A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivoAtsunori Kaneshige, Longchuan Bai, Mi Wang, et al.Molecular Cell|September 15, 2022
Structural basis for product specificities of MLL family methyltransferasesYanjing Li, Lijie Zhao, Yuebin Zhang, et al.Biorxiv : the Preprint Server for Biology|June 22, 2026
A U1-U3 snRNA-snoRNA interaction couples SF3B1 mutation to chromatin-state rewiring and genome instabilityPeng Xia, Han Li, Yiyi Ji, et al.Journal of Medicinal Chemistry|June 29, 2023
Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate CancerXin Han, Lijie Zhao, Weiguo Xiang, et al.Journal of Medicinal Chemistry|September 8, 2023
Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate CancerWeiguo Xiang, Lijie Zhao, Xin Han, et al.Pageof 13